Anixa Biosciences issued Canadian patent for CAR-T cancer therapy technology

Anixa Biosciences announced that the Canadian Intellectual Property Office has issued a Canadian Patent covering Anixa’s novel Chimeric Antigen Receptor-T cell – CAR-T – cancer treatment technology, which has been licensed from The Wistar Institute and is being developed in partnership with Moffitt Cancer Center. The patent covers a nucleic acid that encodes a chimeric protein whose domains can be used to treat certain types of cancer by binding to specific hormone receptors and activating T cells. The patent was invented by doctors formerly of The Wistar Institute, to which the patent is assigned, along with Anixa’s majority-owned subsidiary, Certainty Therapeutics, which is the exclusive, world-wide licensee.